Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;37(11):e1318-e1320.
doi: 10.1111/jdv.19307. Epub 2023 Jul 11.

Pathological complete response to neoadjuvant pembrolizumab in a patient with metastatic cutaneous squamous cell carcinoma

Manon Blaise  1 , Gilles Poissonnet  2 , Nathalie Cardot-Leccia  3 , Anne Sudaka  4 , Marine Velin  1 , Madleen Chassang  5 , Micheline Razzouk-Cadet  6 , Alexandra Picard-Gauci  1 , Thierry Passeron  1   7 , Henri Montaudié  1   7
Affiliations

Pathological complete response to neoadjuvant pembrolizumab in a patient with metastatic cutaneous squamous cell carcinoma

Manon Blaise et al. J Eur Acad Dermatol Venereol. 2023 Nov.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20:6582-6592.
    1. Alberti A, Bossi P. Immunotherapy for cutaneous squamous cell carcinoma: results and perspectives. Front Oncol. 2021;11:727027.
    1. Krishnamoorthy M, Lenehan JG, Maleki VS. Neoadjuvant immunotherapy for high-risk, Resectable malignancies: scientific rationale and clinical challenges. J Natl Cancer Inst. 2021;113:823-832.
    1. Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387:1557-1568.
    1. Lee AY, Brady MS. Neoadjuvant immunotherapy for melanoma. J Surg Oncol. 2021;123:782-788.

MeSH terms

LinkOut - more resources